Evans' syndrome complicating chronic graft versus host disease after cadaveric liver transplantation.

Acute graft versus host disease (GVHD) occurred in a patient after cadaveric liver transplantation from an HLA disparate donor. Immunosuppression resulted in a remission, but chronic GVHD with a scleroderma-like syndrome ensued. This was further complicated by immune hemolytic anemia and thrombocytopenia (Evan's syndrome). Semi-quantitative microsatellite analysis of circulating lymphoid cells showed that T cells were predominantly of donor origin, thereby explaining the chronic GVHD. The marrow hematopoietic cells remained recipient, so that the immune cytopenias were expected to be alloimmune in nature. However, the red cell antibodies were shown to have anti-C and anti-e specificity, with both the donor (R1R1) and recipient (R1r) possessing the C and e antigens. Therefore, the immune hemolysis might be considered both alloimmune and autoimmune. The patient finally died of sepsis. This case illustrates that chronic GVHD due to stable donor T cell engraftment may rarely occur in liver transplantation despite HLA disparity. Immunosuppression may result in dysregulation of T cell functions, leading to alloimmune and autoimmune problems.
AuthorsW Y Au, C M Lo, B R Hawkins, E S Ma, A K Lie, Y L Kwong
JournalTransplantation (Transplantation) Vol. 72 Issue 3 Pg. 527-8 (Aug 15 2001) ISSN: 0041-1337 [Print] United States
PMID11502987 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
  • Adult
  • Anemia, Hemolytic (etiology)
  • Cadaver
  • Chronic Disease
  • Fatal Outcome
  • Graft vs Host Disease (etiology)
  • Humans
  • Liver Transplantation (adverse effects)
  • Male
  • Syndrome
  • Thrombocytopenia (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: